Pembrolizumab in Combination With Lenvatinib (Keytruda and Lenvima)


CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. 
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. 
This review assesses pembrolizumab in combination with lenvatinib (Pembrolizumab: powder for solution for infusion 50 mg, or solution for infusion 100 mg/4 mL vial IV infusion over 30 minutes; lenvatinib: 4 mg and 10 mg capsules [as lenvatinib mesylate], oral). 
Indication: Adult patients with advanced endometrial carcinoma that is not MSI-H or dMMR who have disease progression following prior platinum-based systemic therapy and are not candidates for curative surgery or radiation. 
